Results 21 to 30 of about 40,207 (286)
Proteomic and clinical biomarkers for acute mountain sickness in a longitudinal cohort
Communications Biology, 2022 Potential acute mountain sickness diagnostic, predictive, protective biomarkers are established using plasma proteomic, clinical and symptom phenotype data with machine learning approaches in a longitudinal cohort of 53 individuals.
Jing Yang +6 more
doaj +1 more source
Effects of age on hypoxic tolerance in women
Current Issues in Sport Science, 2023 Introduction The prevalence of acute mountain sickness (AMS) is increasing with altitude (i.e., 10-25% at 2,500 m and 50-85% at ~ 5,000 m; Bärtsch & Swenson, 2013). While there is no error-free test to predict its occurrence, several risk factors and
Tom Citherlet +3 more
doaj +1 more source
Age as a risk factor for acute mountain sickness upon rapid ascent to 3,700 m among young adult Chinese men. [PDF]
, 2014 BackgroundThe aim of this study was to explore the relationship between age and acute mountain sickness (AMS) when subjects are exposed suddenly to high altitude.MethodsA total of 856 young adult men were recruited.
Ding, Xiao-han +7 more
core +3 more sources
High Altitude Medicine & Biology, 2002 AFIT 57-YEAR-OLD MALE trekker/climber presented at Dingboche, Nepal (4420 m), with severely limited exercise tolerance (it was an effort for him to walk from his room to the dining area), headache, and nausea. These symptoms first appeared 2 days earlier when he returned to Lobouche (5029 m) after climbing Kalapatar (5600 m).
Taylor, A +10 more
openaire +3 more sources
Prevention and treatment of high altitude cerebral edema (HACE)
Journal of Education, Health and Sport, 2020 High altitude cerebral edema (HACE) is often a severe and potentially fatal manifestation of acute mountain sickness (AMS). It usually develops within the first 2 in individuals rapidly ascending at altitudes above 4000 m.
Karol Mazur +4 more
doaj +1 more source
Does This Patient Have Acute Mountain Sickness?: The Rational Clinical Examination Systematic Review. [PDF]
, 2017 Acute mountain sickness (AMS) affects more than 25% of individuals ascending to 3500 m (11 500 ft) and more than 50% of those above 6000 m (19 700 ft).
Collet, T.H. +6 more
core +2 more sources
High-altitude illness: Management approach
Turkish Journal of Emergency Medicine, 2019 In high altitudes, usually above 2500 m, travelers are faced with decreased partial pressure of oxygen along with decreased barometric pressure. High-altitude illness, a syndrome of acute mountain sickness, high-altitude cerebral edema and high-altitude ...
Gökhan Aksel +2 more
doaj +1 more source
Variants of the low oxygen sensors EGLN1 and HIF-1AN associated with acute mountain sickness. [PDF]
, 2014 Two low oxygen sensors, Egl nine homolog 1 (EGLN1) and hypoxia-inducible factor 1-α inhibitor (HIF-1AN), play pivotal roles in the regulation of HIF-1α, and high altitude adaption may be involved in the pathology of acute mountain sickness (AMS).
Huang, Lan +5 more
core +3 more sources
Journal of The Nepal Medical Association- Editorial
Journal of Nepal Medical Association, 2003 Man And The Mountains HIgh Altitude Pulmonary Oedema And Acute Mountain ...
JNMA Editorial
doaj +1 more source
Smartphone-Enabled Heart Rate Variability and Acute Mountain Sickness [PDF]
, 2017 INTRODUCTION: The autonomic system and sympathetic activation appears integral in the pathogenesis of acute mountain sickness (AMS) at high altitude (HA), yet a link between heart rate variability (HRV) and AMS has not been convincingly shown.
Bakker-Dyos, J +5 more
core +2 more sources